Volume | 102,533 |
|
|||||
News | - | ||||||
Day High | 1.40 | Low High |
|||||
Day Low | 1.25 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
BioSig Technologies Inc | BSGM | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.31 | 1.25 | 1.40 | 1.27 | 1.33 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
654 | 102,533 | $ 1.31 | $ 134,029 | - | 0.2619 - 16.50 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:39:36 | 96 | $ 1.25 | USD |
BioSig Technologies Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
11.67M | 9.33M | - | 18k | -29.05M | -3.11 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
BioSig Technologies News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BSGM Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.61 | 2.00 | 1.25 | 1.72 | 232,063 | -0.34 | -21.12% |
1 Month | 1.55 | 2.44 | 1.04 | 1.74 | 1,428,515 | -0.28 | -18.06% |
3 Months | 0.7911 | 2.98 | 0.2619 | 1.36 | 1,264,269 | 0.4789 | 60.54% |
6 Months | 4.209 | 4.999 | 0.2619 | 1.73 | 771,405 | -2.94 | -69.83% |
1 Year | 13.30 | 16.50 | 0.2619 | 5.42 | 649,348 | -12.03 | -90.45% |
3 Years | 31.60 | 45.80 | 0.2619 | 10.66 | 414,677 | -30.33 | -95.98% |
5 Years | 76.50 | 124.30 | 0.2619 | 33.54 | 417,382 | -75.23 | -98.34% |
BioSig Technologies Description
BioSig Technologiesis an advanced medical technology company bringing never-before-seen insights to the treatment of cardiovascular arrhythmias. Through collaboration with physicians, experts, and healthcare leaders across the field of electrophysiology (EP), BioSig is committed to addressing healthcare¿s biggest priorities-saving time, saving costs, and saving lives. The Company¿s first product, the PURE EP¿ System, an FDA 510(k) cleared non-invasive class II device, provides superior, real-time signal visualization allowing physicians to perform insight-based, highly targeted cardiac ablation procedures with increased procedural efficiency and efficacy. The global EP market is projected to reach $16B in 2028 with an 11.2% growth rate. |